The median PFS time of patients with low HNF3β expression in the tumor was 20 months (95% CI 16.45–23.55) while that of patients with high HNF3β tumor expression was 30 months (95% CI 13.23–46.77). This evidence concerns the gene FOXA2 and neoplasm.